Search Results - "Bogaert, Liz"

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy by Yadav, Rajbharan, Schubbert, Suzanne, Holder, Patrick G, Chiang, Eugene Y, Kiabi, Nargess, Bogaert, Liz, Leung, Irene, Rashid, Rumana, Avery, Kendra N, Bonzon, Christine, Desjarlais, John R, Sanjabi, Shomyseh, Sharma, Amy, Lepherd, Michelle, Shelton, Amy, Chan, Pam, Liu, Yanqiu, Joslyn, Louis, Hosseini, Iraj, Stefanich, Eric G, Kamath, Amrita V, Bernett, Matthew J, Shivva, Vittal

“…Interleukin 15 (IL-15) is a potential anticancer agent and numerous engineered IL-15 agonists are currently under clinical investigation. Selective targeting…”
Get full text

784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors by Mallet, William, Gadkari, Rishali, Pearson, Cecelia, Torrez Dulgeroff, Laughing Bear, Luo, Angela, Luo, AAngela Luondrew, Melrose, Jennifer, Nolin, Jess, Lee, Arthur, Zhou, Matthew, Anand, Puneet, Sarma, Ganapathy, Henning, Karla, Blum, Lisa, Chapin, Steven, Bogaert, Liz, Ackerman, Shelley, Kudirka, Romas, Shen, Yuyi, Husain, Amreen, Perez, Edith, Kowanetz, Marcin, Alonso, Michael, Safina, Brian, Dornan, David

“…BackgroundCEA (CEACAM5) is a well-validated cell-surface antigen that is highly expressed in multiple solid tumors. Bolt's immune-stimulating antibody…”
Get full text

Complex PK-PD of an engineered IL-15/IL-15Rα–Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics by Lu, Dan, Yadav, Rajbharan, Holder, Patrick, Chiang, Eugene, Sanjabi, Shomyseh, Poon, Victor, Bernett, Matthew, Varma, Rajat, Liu, Ke, Leung, Irene, Bogaert, Liz, Desjarlais, John, Shivva, Vittal, Hosseini, Iraj, Ramanujan, Saroja

“…•A QSP model quantified the PD-enhanced TMDD of an engineered cytokine in cynos.•The model simultaneously described PK and PD of several lymphocyte…”
Get full text

CD123 Directed IgM Antibody-based T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release by Liu, Liqin, Li, Gene, Wang, Ling, Yakkundi, Poonam, Hinton, Paul R., Pandya, Deepal, Amoury, Manal, Sekar, Keerthana, Liu, Chian, Rosete, Rodnie, Hanna, Nardeen, Kotturi, Maya F., Bogaert, Liz, Hong, Jiyoung, Tsai, Christina, Keyt, Bruce A., Sinclair, Angus M.

Get full text

Novel CD123xCD3 Bispecific Igm Antibody, Igm-2537, Potently Induces T-Cell Mediated Cytotoxicity of Acute Myeloid Leukemia Cells In Vivo and in Vitro with Minimal Cytokine Release by Li, Gene, Ye, Zhongde, Yakkundi, Poonam, Manlusoc, Marigold, Logronio, Kathryn, Tahrani, Leyla, Rosete, Rodnie, Bernados, David, Hinton, Paul, Pandya, Deepal, Hanna, Nardeen, Anantam, Jey, Kotturi, Maya F, Bogaert, Liz, Hong, Jiyoung, Tsai, Christina, Manley, Thomas, Keyt, Bruce A, Sinclair, Angus M., Liu, Liqin

“…Introduction: New therapeutics are needed for the effective treatment of acute myeloid leukemia (AML), as standard chemotherapeutics are poorly tolerated and…”
Get full text

Abstract 2286: XmAb30819, an XmAb®2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies by Nisthal, Alex, Lee, Sung-Hyung, Kim, Yoon Kyung, Bonzon, Christine, Rashid, Rumana, Avery, Kendra N., Bogaert, Liz, Ardila, Connie, Leung, Irene W., Rodriguez, Nicole, Muchhal, Umesh S., Moore, Gregory L., Chu, Seung Y., Desjarlais, John R.

“…Abstract Bispecific T cell engagers simultaneously bind CD3 on T cells and tumor-associated antigens to promote T cell-mediated killing of tumor cells. While…”
Get full text

Regulatory T Cell Selective IL-2-Fc Fusion Proteins for the Treatment of Autoimmune Diseases by Varma, Rajat, Liu, Ke, Avery, Kendra, Rashid, Rumana, Schubbert, Suzanne, Leung, Irene, Bonzon, Christine, Bogaert, Liz, Desjarlais, John, Bernett, Matthew J.

“…Regulatory T cells (Tregs) characterized as CD4 positive cells, expressing CD25 (IL-2Rα) and the forkhead transcription factor FoxP3 maintain immune tolerance…”
Get full text

Abstract 5565: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure by Bernett, Matthew J., Varma, Rajat, Bonzon, Christine, Rashid, Rumana, Bogaert, Liz, Liu, Ke, Schubbert, Suzanne, Avery, Kendra N., Leung, Irene W., Rodriguez, Nicole, Chu, Seung Y., Muchhal, Umesh S., Moore, Gregory L., Desjarlais, John R.

“…Abstract IL15 and IL2 are two similar cytokines that stimulate the proliferation of lymphocytes, and their therapeutic potential has been well established in…”
Get full text

Abstract 2784: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation by Hedvat, Michael, Bonzon, Christine, Bernett, Matthew J., Moore, Gregory L., Avery, Kendra, Rashid, Rumana, Nisthal, Alex, Schubert, Suzanne, Varma, Rajat, Lee, Sung-Hyung, Bogaert, Liz, Leung, Irene W.L., Chu, Seung, Muchhal, Umesh, Desjarlais, John

“…Abstract Combination checkpoint blockade promotes productive anti-tumor clinical responses often associated with an increase in immune-related adverse events…”
Get full text

Abstract 1639: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation by Moore, Gregory L., Hedvat, Michael, Bernett, Matthew J., Varma, Rajat, Schubbert, Suzanne, Bonzon, Christine, Avery, Kendra N., Rashid, Rumana, Nisthal, Alex, Bogaert, Liz, Leung, Irene W., Chu, Seung Y., Muchhal, Umesh S., Desjarlais, John R.

“…Abstract Tumor infiltrating lymphocytes (TILs) express multiple checkpoint receptors, in contrast to lymphocytes found in the periphery (Matsuzaki et al PNAS…”
Get full text

Abstract 2933: Novel CD123xCD3 bispecific IgM antibody, IGM-2537, potently induces T-cell mediated cytotoxicity of acute myeloid leukemia cells with minimal cytokine release by Li, Gene, Wang, Ling, Yakkundi, Poonam, Hinton, Paul, Pandya, Deepal, Sekar, Keerthana, Rosete, Rodine, Ye, Zhongde, Hanna, Nardeen, Kotturi, Maya F., Bogaert, Liz, Hong, Jiyoung, Tsai, Christina, Manley, Thomas, Keyt, Bruce A., Sinclair, Angus M., Liu, Liqin

“…Abstract Novel therapeutics are needed for the effective treatment of acute myeloid leukemia (AML), as standard chemotherapeutics are poorly tolerated and ~50%…”
Get full text